Public vaccine company Novavax announced today that it will receive up to $388 million from the Coalition for Epidemic Preparedness to continue development and manufacturing of its COVID-19 vaccine candidate.development, look at a sample of a respiratory virus at Novavax labs in Rockville, Maryland on March 20, 2020, one of the labs developing a vaccine for the coronavirus, COVID-19.
Novavax’s candidate is a “subunit vaccine,” where just a part of the virus is injected into the body to create antibodies that can protect against a COVID-19 infection. The company plans to start phase 1 human clinical trials of the vaccine in mid-May and announce preliminary results of the vaccine in July.
Money from the grant will be used to fund a safety trial this month in Australia and to fund scaling up of the manufacturing infrastructure needed to make 100 million doses of the vaccine by the end of the year.In a press release, CEPI CEO Richard Hatchett said this investment was the organization’s largest ever. “
Our vaccine R&D programs are starting to show progress, so it is vital that we invest now to boost manufacturing capacity,” he said.Novavax is one of many companies working to create a vaccine against COVID-19. While it is going into phase 1 trials quickly compared to normal vaccine development, it still lags behind some of its competitors. Last week
Visit Madagascar...
Obamagate
And that's why they 'refuse' to believe it's not a virus.